Additional proof of concept data consistent and strengthen data set shared at ASH 2025Management to host meetings at JP Morgan 44th Annual Healthcare Conference 2026 SAN FRANCISCO, CALIFORNIA / ACCESS ...

The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and ...

Bitopertin was awarded the Commissioner’s National Priority Review Voucher (CNPV) and NDA is currently under FDA reviewUpdated data from the Phase 2 study of DISC-0974 in patients with myelofibrosis ...

Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in ...

Shune, MD, discusses results from an interim safety analysis of a randomized phase 2 study exploring axatilimab in ...

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...

MRM Health has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) ...

Ramp up of Phase 1 concentrator advancing to plan; first sale of concentrate completed Shaft #3 on track for April 2026; five ...

After greenlighting 56 novel therapeutics in 2025, four notable applications continue to await the agency’s action after ...

HANGZHOU, China, SHANGHAI and BOSTON, Jan. 12, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical stage innovative drug development ...